BioMarin Pharmaceutical enters the back half of May with an unusual split: the Street is broadly bullish, Goldman Sachs just stepped off the buy side, and short sellers have been adding with quiet persistence.
The analyst picture this week is the headline story. Goldman Sachs reinstated coverage on May 11 with a Neutral and a $69 target — down from a prior Buy — a meaningful step back from one of the most-watched desks on Wall Street. That move landed in the middle of a wider post-earnings recalibration. Since Q1 results on May 4, Morgan Stanley trimmed its target to $119 from $120 (Overweight maintained), Bernstein cut harder to $82 from $94 (Outperform), and RBC held at $66 on a Sector Perform. The consensus is still officially Buy, and the mean target is $87.88, implying roughly 76% upside to the $49.81 close — but the direction of travel on individual targets is unmistakably lower, with BofA Securities on Tuesday lowering to $80 and Citigroup initiating at $75 with a Buy, adding fresh coverage that still sits well above the current price. The breadth of the target range — from $66 to $120 — illustrates how wide the disagreement is. The factor score for analyst recommendation divergence ranks in the 91st percentile, which confirms that the Street is genuinely split on the risk-reward here.
The bear case centres on competition in growth hormone and short stature indications and IP risks in the orphan disease space. Bulls counter with pipeline depth, rare-disease franchise durability, and a 12-month forward EPS growth trajectory that ranks in the 89th percentile of the universe. Valuation is not stretched: the P/E runs at 9x and EV/EBITDA at 7.7x, both down on the month as the stock has shed 9% in 30 days and 6% this week. RSI has dropped to 32.5, deep into oversold territory. The stock is also down 16% year-to-date. On paper, the numbers look cheap. In practice, cheap can get cheaper when a company's forward narrative is contested.
Short positioning tells a supporting story for the bears — not dramatic, but persistent. Short interest % of free float has climbed to 5.77%, up from 4.4% in early April. That is a 24% expansion in shares short over the past month, with the bulk of the move coming in late April when SI jumped by roughly half a percentage point in a single week. The borrow market, however, provides no urgency signal in either direction: availability is vast at over 3,800% of current short interest, meaning there are far more shares available to lend than are actually borrowed. Cost to borrow is negligible at 0.35%, down 20% on the week. Shorts are building, but there is nothing in the lending market to suggest they face any friction doing so.
Options are telling a different story from the short book. The put/call ratio has dropped to 0.31 — a two standard-deviation move below its 20-day average of 0.36, and the lowest level recorded in the past 52 weeks. That means options traders are leaning heavily toward calls relative to puts, the most bullish positioning seen all year, even as the stock has been falling. This divergence between a rising short position and heavily call-skewed options flow is the sharpest tension in the setup right now: one side is hedging or speculating on further downside, the other is buying upside.
Institutional ownership provides some ballast. Fidelity (FMR LLC) added over 1.7 million shares in the most recent filing period, bringing its stake to roughly 3.5 million shares. Capital Research built by nearly 1 million shares, AQR added over 1 million, and Viking Global added just over 1 million. Citadel entered the top-15 holders with a new 4.5 million share position, the largest single-period addition among the top holders. Against that, the insider track has been exclusively sales: the CEO, CFO, CTO, Chief Legal Officer, and Chief Commercial Officer all sold shares in March at prices between $56 and $58 — well above where the stock now trades. The most recent registered trade was an EVP sale on May 7 at $53.85.
The next scheduled event is the Q2 earnings call, pencilled for July 31. After three consecutive first-day post-earnings declines averaging around 1.4%, the earnings reaction history is muted rather than volatile. What to watch between now and then is whether the call-heavy options positioning proves prescient — or whether the Goldman re-rating and steady short accumulation reflect a more structural reassessment of BMRN's growth premium.
See the live data behind this article on ORTEX.
Open BMRN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
